ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
our overdraft finance so that you have one flexible account for both personal/ business mortgages and overdraft
Small Firms Loan Guarantee Scheme
Up to two years trading: Up to ?100,000
Over two years trading: Up to ?250,000
However these are difficult to obtain and are a loan of last resort.
Export Guarantee Scheme
This is government backed insurance against a
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
propriate export documentation.
Mezzanine
This is a halfway house between loan and equity. It can be an innovative way of raising funds for the more established business. Mostly for expansion capital.
Equity
This is not as easy as the papers would have you know. Only 1% of business plans received by Venture Capital Funds are successful. Howeve
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
?25,000 to ?250,000 but can go as high as ?2m for the right opportunity. Exit within 3-5 years.
Venture CapitalThese are investment funds seeking high rates of return. However typically investments are over a million pounds. Some funds are targeted at lower amounts depending upon the sector and region. These funds are looking for exponential capital growth over 3-5 years.
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
quote>
Asset backed financeThis can cover machinery, sales invoices even sales orders. It can be a very flexible source of finance to the growing business
Leasing
This will cover your capital expenditure and spread the cost over a three to five year period. It is particularly useful if you do not have taxable profits to maximise your capital a
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
llowances.
Sale and leaseback of a property you own is another good source of funds.
Factoring
Factoring offers a sales ledger administration and debt collection service. Up to 95% of an approved sales invoice is paid within 48 hours, quicker if required. Credit protection is also available to protect against a bad debt. The Factor will own and place a first charge over the book d
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
bts and they might also take other charges, depending upon the strength of the financial information.
Invoice discounting
Invoice Discounting can be Confidential or Disclosed; it depends upon the strength of the financial information. The service is the same as Factoring, except that the sales ledger administration and the debt collection is the responsibility of the client and not
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
the Factor. Pre payment of the approved sales invoice is still up to 95% and the factor will still have a first charge on the book debt and therefore own the debt. This service can also have credit protection cover. All sales invoices need to be for a business to business debt, and some proof of delivery is generally required.
Trade Finance
This is funding provided against stock p
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
rchases, signed contracts and orders whereby the funder will prepay a certain percentage of the value
Pension fund
It may be possible to use your pension funds for a loan back to the business
Business Relationship Funding
This is another source of funds that can be overlooked. It may be possible to introduce potential alliances to add value
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
to both parties. It may produce an ultimate exit route in the medium to long term.
- Joint Ventures: Requires a legal agreement embodying the deal and another company
- Partnerships: Two companies collaborate with possible funding.
- Joint working relationships: These are an informal partnership which may be
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
more project specific where the parties can share resources.
Agencies: These can be geographical or product specific and generally incorporates a payment for the right to the agency.Distributors: Very like an agency but may not necessarily involve up front payment.Alliances: These do not require a separate company and can be.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
embodied by a legal agreement to work together.
Trade investors: Otherwise known as Corporate Partnering. This can be a good way to involve a much larger company in the business with a view to possible trade sale further down the line.Associates: This can be a loose arrangement with no fundamental commitments either way, rather like a preferred supplelopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
ier.
Equity Swop: Two companies exchange shares to a similar value to develop both businesses.Franchises: This can allow the business to grow without further direct investment.Licensing: This involves licensing a product or service to enable others to sell it. This requires you to own the intellectual property.
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products